Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
55–90
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Best corrected visual acuity (ETDRS scale) of 60 letters or less in the study eye.
An active choroidal neovascular membrane attributable to neovascular AMD in at least one eye.
History of treatment (at any time) with at least 3 doses of anti-VEGF therapy in the study eye.
You may not be if
History of recurrent non-response to anti-VEGF therapy in the study eye.
In the study eye, retinal disease other than AMD (benign conditions of the vitreous and peripheral retina are not exclusionary).
Choroidal neovascularization due to a cause other than AMD.
In the study eye, media opacity that, in the investigator's opinion, could interfere with conduct of the study.
History of infectious uveitis or endophthalmitis in either eye.
Any of the following treatments to the study eye within 28 days prior to dosing: ranibizumab, bevacizumab, pegaptanib or other VEGF inhibitor.
Any of the following within 90 days prior to dosing: photodynamic therapy or laser photocoagulation in the study eye; intravitreal steroid in the study eye; or intraocular surgery (including cataract surgery) in the study eye
Clareo Health | Safety and Efficacy of Intravitreal LFG316 in Wet Age Related Macular Degeneration (AMD)
